PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

NCT00446446 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen